Mark G. Kris, MD, FASCO shares an overview of existing treatment options for patients with stage I-III non-small cell lung cancer.
Back
Post-Conference Perspectives: ctDNA for MRD in Lung Cancer
Mark G. Kris, MD, FASCO provides insight on monitoring patients with NSCLC and discusses the developing role of ctDNA.
Post-Conference Perspectives: ctDNA for MRD in Lung Cancer
Episodes
All
All
Practical advice on monitoring options for patients with NSCLC treated with definitive radiation therapy or surgery.
Dr. Mark Kris shares insight on ctDNA and its use in detecting MRD in NSCLC.
A comprehensive review of data presented at ASCO 2022 on ctDNA and MRD detection in NSCLC.
A thoracic oncology expert provides perspective on ctDNA as a tool and its future as part of the NSCLC landscape.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026
5